Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Arthroplasty (TKA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, 18 years of age or older.~* Written informed consent and written authorization for use or release of health and research study information have been obtained.~* Subject has chronic Prosthetic knee joint pain for more than 3 months.~* Subject has pain 6 or greater on a 10 point Numerical Pain Rating scale~* Ability to follow study instructions and likely to complete all required visits.~* Negative urine pregnancy test on the day of treatment prior to the administration of study medication (for females of childbearing potential). (if applicable)~* Negative infectious etiology workup (joint aspiration, serological parameters such as Erythrocyte Sedimentation Rate (ESR) or C-reactive protein (CRP) and clinical examination).~* Patients who were considered not to be candidates for Prosthetic knee joint revision surgery and have failed traditional treatments including oral pain medications, as determined by referring orthopedic surgeon~Exclusion Criteria:~* Use of aminoglycoside antibiotics, curare-like agents, or other agents that might interfere with neuromuscular function.~* Any medical condition that may put the subject at increased risk with exposure to BOTOX ®including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or known disorders of neuromuscular function~* Females who are pregnant, breast-feeding, or planning a pregnancy during the study or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.~* Know allergy or sensitivity to any of the components in the study medication.~* History of recent or ongoing alcohol or drug abuse.~* Known, uncontrolled systemic disease.~* Concurrent participation in another research study~* Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.~* Patients whose pain is rated as less than 6 on a 10 point Numerical Pain Rating scale at the screening visit

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Single Intra-articular Injection of 100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
- B (Type: PLACEBO_COMPARATOR): Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit

Based on this trial design, predict the completion outcome and termination type (if applicable).